Skip to main content
SpringerLink
Log in

Therapie der pulmonalen arteriellen Hypertonie (PAH) mit dem oralen Endothelin-Rezeptor Antagonisten Bosentan bei systemischer Sklerose: Die BREATHE-1-Studie und klinische Erfahrungen

Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience

  • KLINISCHE STUDIEN KURZGEFASST
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ahmadi-Simab K, Lamprecht P, Gross WL (2003) Erfolgreiche Therapie der Kollagenose-assoziierten pulmonalarteriellen Hypertonie (PAH) unter Bosentan (Abstract). Endothelinantagonisten-Symposium. Essen, 11. 10. 2003

  2. Channick R, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 358:1119–1123

    Article  CAS  PubMed  Google Scholar 

  3. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343–349

    CAS  PubMed  Google Scholar 

  4. McLaughlin V, Sitbon O, Rubin LJ (2003) The effect of first-line bosentan on survival of patients with primary pulmonary hypertension (Abstract). Meeting of the American Thoracic Society, 19. 5. 2003

    Google Scholar 

  5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Poliklinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck und Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538, Lübeck, Germany

    K. Ahmadi-Simab,  P. Lamprecht,  B. Hellmisch &  W. L. Gross

Authors
  1. K. Ahmadi-Simab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Lamprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Hellmisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. L. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Ahmadi-Simab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmadi-Simab, K., Lamprecht, P., Hellmisch, B. et al. Therapie der pulmonalen arteriellen Hypertonie (PAH) mit dem oralen Endothelin-Rezeptor Antagonisten Bosentan bei systemischer Sklerose: Die BREATHE-1-Studie und klinische Erfahrungen. Z Rheumatol 63, 495–497 (2004). https://doi.org/10.1007/s00393-004-0594-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-004-0594-3

Search

Navigation